- TypeConference
- Location Berlin, Germany
- Date 24-01-2023 - 26-01-2023
Medical/Healthcare/Hospital
Built with biopharmaceutical industry insights, this meeting will unite KOLs from Europe and the rest of the world to delve into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines and therapeutics with improved specificity, delivery and efficacy for immuno-oncology, infectious diseases and beyond.
Hear from 35+ pioneering large pharma, biotech, and academic experts who are shaping the landscape of mRNA-based therapeutics and discover how they are addressing the major challenges facing the industry.
With more companies investing in their tools and technologies to innovate processes and technologies to address key challenges such as sequence optimization, cell-specific payload expression, and durability, there has never been a more pivotal time to join European biopharma experts and discuss the following topics.
-Emerging cell-enhancing or protein replacement therapies based on mRNA
-Optimization of analytical and quality control protocols
-Durability, accessibility and immunogenicity challenges of mRNA therapeutics and vaccines
-Enhancement of formulation, process development and manufacturing processes
-Need for clear regulatory path to support the technology whilst enabling speed to market
To learn more, download your copy of the full event guide including all speakers and their session details: https://ter.li/94wpbg
Speakers: Andreas Kuhn Senior Vice President RNA Biochemistry and Manufacturing, RNA Biochemistry and Manufacturing BioNTech, Mostafa Nakach Global Head of Process Engineering for Biologic Drug Product Development Sanofi, Giovanna Lollo Associate Professor Universite Claude Bernard Lyon, Cristina Bruno Program Manager - mRNA Technology Transfer World Health Organization, Oliver Ernst Managing Director, Chief Operating Officer NEUWAY Pharma, Daniel Tondera Head of Biology Pantherna Therapeutics, Aviad Pato Head of Research and Natural Killer Cells Gamida Cell, Louis St.L. O'Dea Chief Medical Officer and President BIORCHESTRA, Cees J.M. van Rijn Professor of Nanotechnology and Microfluidics University of Amsterdam, Valeria Chiono Professor, Department of Mechanical and Aerospace Engineering Politecnico di Torino, Khalid Khabar Director of Molecular BioMedicine Program King Faisal Specialist Hospital and Research Centre, Nagy Habib Professor, Head of Surgery, Hammersmith Campus Imperial College London, Ioana Panait Lead Research Analyst Beacon Targeted Therapies, May Guo Vice President, Nucleic Acids Arranta Bio
Brochure: https://go.evvnt.com/1292101-0?pid=6581